Overview
Title
To amend the Public Health Service Act to end the liability shield for vaccine manufacturers, and for other purposes.
ELI5 AI
The bill wants to make it so people can take vaccine makers to court if they believe a vaccine has hurt them or caused a death, even if they haven't asked for special compensation money first. It also says that COVID-19 vaccines won't get some legal protections that other vaccines do.
Summary AI
H.R. 9828, titled the "End the Vaccine Carveout Act," aims to remove the liability protections for vaccine manufacturers. This bill allows individuals to bring civil lawsuits against vaccine makers and administrators for injuries or deaths related to vaccines, regardless of whether they have filed for compensation through the National Vaccine Injury Compensation Program. It modifies several sections of the Public Health Service Act to allow for these legal actions and excludes COVID-19 vaccines from certain legal protections under the definition of a "covered countermeasure."
Published
Keywords AI
Sources
Bill Statistics
Size
Language
Complexity
AnalysisAI
The proposed legislation, titled the "End the Vaccine Carveout Act," aims to amend specific provisions within the Public Health Service Act, particularly concerning the liability protections currently extended to vaccine manufacturers and administrators. The bill notably advocates for eliminating these protections, thereby allowing individuals to bring civil lawsuits against vaccine manufacturers or administrators for vaccine-related injuries or deaths. Moreover, it seeks to exclude COVID-19 vaccines from the definition of "covered countermeasures," potentially subjecting them to increased litigation.
General Summary of the Bill
The "End the Vaccine Carveout Act" intends to dismantle existing liability shields that protect vaccine manufacturers and administrators from legal action related to vaccine injuries or deaths. This proposed change would allow individuals to file lawsuits in state or federal courts for damages, even if they have not previously sought compensation through the National Vaccine Injury Compensation Program (VICP). The bill also aims to redefining "covered countermeasures" to exclude COVID-19 vaccines, thus exposing them to potential litigation despite being authorized for emergency use.
Significant Issues
Several significant issues arise from this bill. First, the removal of liability protections could lead to a surge in litigation against vaccine manufacturers, possibly resulting in higher legal costs and affecting vaccine distribution and access. Second, the option to file petitions for compensation under the VICP at any time may lead to administrative backlogs and inefficiencies. The bill's exclusion of COVID-19 vaccines from the "covered countermeasures" category might undermine emergency preparedness and public health initiatives. Furthermore, the complex legal amendments proposed could result in increased uncertainty and litigation complexities.
Impact on the Public Broadly
For the general public, the bill's potential effects are concerning. By increasing litigation risks for vaccine producers, the bill might deter companies from developing or distributing vaccines, which could limit the availability of vaccines during public health emergencies. This could affect the entire population's ability to access necessary vaccines promptly and safely. Additionally, should administrative backlogs occur due to the ability to file compensation petitions at any time, it may slow down the compensation process for individuals genuinely seeking relief for vaccine-related injuries.
Impact on Specific Stakeholders
The bill could have diverse impacts on different stakeholders. For vaccine manufacturers and administrators, increased exposure to lawsuits could result in significant financial burdens and heightened operational risks. This might push some companies to reconsider their participation in vaccine development and distribution. On the legal front, attorneys specializing in vaccine litigation may see increased demand for their services, though this comes with the complexity of navigating potentially ambiguous legal landscapes.
Conversely, individuals who believe they have suffered vaccine-related injuries may view the bill positively, as it expands their legal recourse options beyond the VICP. However, this could also lead to legal and financial uncertainty for claimants due to longer processing times and variability in court outcomes. Public health officials may find that these changes complicate their efforts to maintain high vaccination rates and manage health crises efficiently.
Ultimately, while the "End the Vaccine Carveout Act" could empower individuals to seek redress for vaccine-related injuries, it also carries the potential to disrupt current public health frameworks and vaccine availability, sparking debate among lawmakers and public health stakeholders.
Issues
The removal of the liability shield for vaccine manufacturers in Section 2 could significantly impact public health by increasing litigation against vaccine manufacturers and administrators, potentially leading to higher legal costs and affecting vaccine availability.
The ability to file a petition for compensation under the National Vaccine Injury Compensation Program at any time, as outlined in Section 2, could lead to a backlog of cases and increased administrative costs, creating inefficiencies in the system.
The exclusion of COVID-19 vaccines from the definition of 'covered countermeasure' in Section 2b might compromise emergency preparedness and public health responses, necessitating additional explanations of the rationale and potential consequences.
The amendments in Section 2 regarding the allowance of civil actions without the restriction of prior petitions could lead to a complex legal landscape with increased uncertainty and potential conflicts in vaccine injury litigation.
The repeal of sections related to election, standards of responsibility, and trial procedures without a clear explanation, as indicated in Section 2, might create gaps in legal protections or lead to unintended consequences in handling vaccine injury cases.
The absence of specific provisions detailing the handling of ongoing cases in light of the proposed changes in Section 2 can generate legal uncertainty and might complicate current litigation or settlement processes.
The complex legal language used in the bill, particularly in Section 2, might be difficult for laypersons to understand, obscuring the bill's intentions and implications and potentially impacting public perception and interpretation.
Sections
Sections are presented as they are annotated in the original legislative text. Any missing headers, numbers, or non-consecutive order is due to the original text.
1. Short title Read Opens in new tab
Summary AI
The first section of the Act states that this piece of legislation can be referred to as the "End the Vaccine Carveout Act".
2. Ending liability shield for vaccine manufacturers Read Opens in new tab
Summary AI
This section proposes changes to existing laws to allow people to sue vaccine makers or administrators for damages from vaccine-related injuries or deaths, even if they have not filed for compensation under the National Vaccine Injury Compensation Program. It also specifically excludes COVID-19 vaccines from being considered as "covered countermeasures," meaning they wouldn't be protected from lawsuits under certain emergency use conditions.